Antimicrobial Compositions and Methods For Reducing Microbial Contamination
20220313598 · 2022-10-06
Inventors
- Joke Geesje Hagting (Groningen, NL)
- Theodorus Adrianus Cornelius Flipsen (Groningen, NL)
- Herbert Wilhelm Ulmer (Groningen, NL)
Cpc classification
A01N25/02
HUMAN NECESSITIES
A01N39/00
HUMAN NECESSITIES
A61K2800/56
HUMAN NECESSITIES
A61K47/32
HUMAN NECESSITIES
A01N39/00
HUMAN NECESSITIES
A61Q17/00
HUMAN NECESSITIES
A61K9/0014
HUMAN NECESSITIES
A01N25/02
HUMAN NECESSITIES
International classification
A61K9/00
HUMAN NECESSITIES
A01N25/02
HUMAN NECESSITIES
A61K47/32
HUMAN NECESSITIES
Abstract
The invention relates to the fields of microbiology and health care, in particular to means and methods for minimizing the spread of hospital-acquired (HA) infections e.g. between patients and healthcare workers. Provided is an antimicrobial composition comprising an antimicrobial agent, a pharmaceutically acceptable carrier material and a polymer, the polymer being an N-vinyl lactam copolymer, and the composition being capable of forming a slow release antimicrobial film when applied to a skin surface.
Claims
1. An antimicrobial composition comprising an antimicrobial agent, a pharmaceutically acceptable carrier material, and an N-vinyl lactam copolymer, wherein said copolymer is obtainable by solution polymerization of vinyl pyrrolidone monomer units (A) and hydrophobically derivatized maleate monomer units (B) of the following general formula: ##STR00009## Wherein R.sub.1 and R.sub.2 are each independently hydrogen or methyl, R.sub.3 and R.sub.4 are each independently selected from hydrogen, and linear and branched C6-C20 alkyl groups, with the exception that both R.sub.3 and R.sub.4 are hydrogen, wherein said polymerization comprises the continuously feeding of a monomer mixture comprising about 70-90 weight % of monomer (A) and about 10-30 weight % of monomer (B), over a predetermined period of time to the reaction mixture.
2. The antimicrobial composition according to claim 1, wherein said monomer mixture comprises 75-90 weight %, of monomer (A) and about 10-25 weight % of monomer (B).
3. The antimicrobial composition according to claim 1, wherein R.sub.3 and R.sub.4 are each independently selected from hydrogen, linear and branched C6-C12 alkyl groups.
4. The antimicrobial composition according to claim 1, wherein R.sub.3 and R.sub.4 are each independently selected from hydrogen, linear and branched C10-C20 alkyl groups.
5. The antimicrobial composition according to claim 1, wherein both R.sub.3 and R.sub.4 are linear C8-C14 alkyl.
6. The antimicrobial composition according to claim 1, wherein R.sub.3 and R.sub.4 are each independently selected from hydrogen and branched C16-C20 alkyl groups.
7. The antimicrobial composition according to claim 1, wherein R.sub.3 or R.sub.4 is hydrogen.
8. The antimicrobial composition according to claim 1, wherein R.sub.3 and R.sub.4 are the same.
9. The antimicrobial composition according to claim 1, wherein the N-vinyl lactam copolymer is present in said composition at a concentration of about 0.5-10 weight percent.
10. The antimicrobial composition according to claim 1, wherein the concentration of antimicrobial agent is between about 0.01 and 2 weight percent.
11. The antimicrobial composition according to claim 1, wherein said antimicrobial agent is selected from the group consisting of quaternium salts, phenols, halogen-releasing compounds, aldehydes, biguanides and polymeric biguanides, amphoterics, iodine-based compounds, peroxygen-based compounds, and silver-containing compounds.
12. The antimicrobial composition according to claim 11, wherein the antimicrobial agent is a quaternary ammonium compound selected from the group consisting of benzethonium chloride, benzalkonium or benzethonium bromide or fluoride, cetyl pyridinium chloride, dequalinium chloride, N-myristyl-N-methyl-morpholinium methyl sulfate, poly[N-[3-(dimethylammonio)propyl]-N′-[3-(ethyleneoxyethelene dimethylammonio)propyl]urea dichloride], alpha-4-[1-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]-omega-tris(2-hydroxyethyl)ammonium chloride, and poly[oxyethylene (dimethyliminio)ethylene (dimethyliminio)-ethylene dichloride].
13. The antimicrobial composition according to claim 1, wherein the pharmaceutically acceptable carrier material is an alcohol, water, an ester, a skin care oil, an emulsifier, emollient, or any mixture thereof.
14. A method for reducing or eliminating the number of micro-organisms on a surface, comprising applying an antimicrobial composition according to claim 1 to said surface and allowing the formation of an antimicrobial film.
15. The method according to claim 14, wherein said surface is the surface of skin, hair and/or nails, or wherein the surface is the surface of a medical device or a personal care product.
16. The method according to claim 14, wherein said micro-organisms are bacteria, viruses, fungi, spores or yeast.
17. A product comprising a composition according to claim 1, the product selected from a skin sanitizer, hand-rub, or (micro)glove.
18. A slow-release carrier for an antimicrobial agent in an antimicrobial film or coating comprising N-vinyl lactam copolymer, wherein said copolymer is obtainable by solution polymerization of vinyl pyrrolidone monomer units (A) and hydrophobically derivatized maleate monomer units (B) wherein (B) is defined according to the following general formula: ##STR00010## R1 and R2 are each independently hydrogen or methyl, R3 and R4 are each independently selected from hydrogen, linear and branched C6-C20 alkyl groups, with the exception that both R3 and R4 are hydrogen, wherein said polymerization comprises the continuously feeding of a monomer mixture comprising about 70-90 weight % of monomer (A) and about 10-30 weight % of monomer (B), over a predetermined period of time to the reaction mixture.
Description
LEGEND TO THE FIGURES
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071] Growth inhibition zones on TSA-plates with S. aureus HG001 after incubation at 37° C. The first well of a 96-well plate was coated with 20 μl formulations based on PVPDDM-80:20 2.5 wt % and 0.45 wt % biocide in alcohol. After drying, 100 μl water was added to the coated well and the plate was incubated for 60 seconds. Next, the aqueous phase was removed from the well. This process was repeated 7 times. Five μ1 aqueous phase of each incubation step was brought on the plate.
[0072] Formulations supplemented with BKC (A), BEZ (B), or PHMBH+Cl—) (C) showed growth inhibition up to the 4.sup.th, 4.sup.th and 3.sup.rd incubation, respectively.
[0073]
[0074]
EXPERIMENTAL SECTION
[0075] Materials and Methods
[0076] Strains and Growth Media
[0077] S. aureus HG001 (21) was grown in TSB or on TSA. Liquid S. aureus HG001 cultures were grown in 96-well plates at 37° C. and under constant agitation using a Biotek powerwave microplate reader.
[0078] Monomer and Co-Polymer Synthesis
[0079] Monomer Synthesis: Octyl Dodecyl Maleate (M20).
[0080] Maleic anhydride (94.70 g, 1.01 mol) and 2-octyl-1-dodecanol (300.51 g, 1.00 mol) were stirred in a molten state at 50° C. for 24 hours. Hexane (600 ml) was added to the homogenous reaction mixture and stirred for 1 h at 60° C. The solution was left overnight at 4° C. and filtered over a Buchner funnel. A bright white powder of M20 (290.10 g, 73%) was obtained.
[0081] Monomer Synthesis: Mono-Decyl Maleate (MDM).
[0082] Maleic anhydride (49.52 g, 0.505 mol) and 1-decanol (79.14 g, 0.500 mol) were stirred in a molten state at 60° C. for 24 hours. Heptane (300 ml) was added to the homogenous reaction mixture and stirred for 1 h at 60° C. The solution was left overnight at 4° C. and filtered over a Buchner funnel. A bright white powder of MDM (96.13 g, 75.0%) was obtained.
[0083] Monomer Synthesis: Di-Decyl Maleate (DDM).
[0084] Maleic anhydride (32.65 g, 0.333 mol) and 1-decanol (110.80 g, 0.700 mol) were stirred in a molten state at 70° C. for 240 hours. The resulting mixture of mono- and di-substituted molecules was separated using ethyl acetate and bicarbonate solution. The DDM was further purified by vacuum distillation at 90° C. A clear, slightly yellow liquid of DDM (45.70 g, 33.1%) was obtained.
[0085] Monomer Synthesis: Mono-Eicosanoyl Maleate (MEM).
[0086] Maleic anhydride (25.14 g, 0.255 mol) and 1-eicosanol (74.64 g, 0.250 mol) were stirred in a molten state at 90° C. for 24 hours. Heptane (300 ml) was added to the homogenous reaction mixture and stirred for 1 h at 90° C. The solution was left overnight at 4° C. and filtered over a Buchner funnel. A bright white powder of MEM (83.29 g, 83.9%) was obtained.
[0087] The table below gives an overview of the copolymers used in the examples:
TABLE-US-00002 Copolymer R3 or R4 R3 or R4 PVPM20-65:35 H Branched C20 PVPM20-80:20 H Branched C20 PVPM20-85:15 H Branched C20 PVPM20-90:10 H Branched C20 PVPMDM-60:40 H Linear C10 PVPMDM-75:25 H Linear C10 PVPMEM-70:30 H Linear C20 PVPDDM-80:20 Linear C10 Linear C10
[0088] Poly[(vinyl pyrrolidone)-co-(octyl dodecyl maleate)] (PVPM20 80/20)
[0089] N-vinyl pyrrolidone (40.63 g, 365.57 mmol) and octyldodecyl maleate (10.02 g, 25.30 mmol) were mixed together to give a clear solution at room temperature (monomer mixture). 0.20 g lauroyl peroxide was added to a 500 ml 3-neck round bottom flask fitted with a mechanical stirrer, a dropping funnel and 200 ml heptane. The monomer mixture was added to the dropping funnel. The entire set-up and reactants were inerted with argon gas and the temperature raised to 70° C. Upon reaching 70° C., the monomer mixture was added over a period of 2 hours. Subsequently 0.1 g lauroyl peroxide was added and the mixture was stirred at 70° C. for another 2 hours. During reaction the polymer precipitated from the solution. The formed polymer was washed three times with water and once with acetone. The collected polymer was dried overnight in an oven at 60° C. White powder of poly[(vinyl pyrrolidone)-co-(octyl dodecyl maleate)] 80/20 (64%) was obtained. The molecular weight of the polymer, determined with GPC using PEG standards, was Mn 23,918 and Mw 35,654. Poly[(vinyl pyrrolidone)-co-(octyl dodecyl maleate)]. The 90/10, 85/10 and 65/35 copolymers were prepared a similar way.
[0090] Poly[(vinyl pyrrolidone)-co-(mono-decyl maleate)] (PVPMDM 60/40, 72/25), and Poly[(vinyl pyrrolidone)-co-(di-decyl maleate)] 80/20 and Poly[(vinyl pyrrolidone)-co-(mono-eicosanoyl maleate)] 70/30 were synthesized in a similar way as poly[(vinyl pyrrolidone)-co-(octyl dodecyl maleate)] 80/20. However the purification was not done by washing with water and acetone, but by dissolving the precipitate formed during the synthesis in IPA (isopropyl alcohol). By subsequently adding the solution drop-wise into heptane, the copolymers precipitate from the solution. The copolymers were collected and dried.
[0091] The copolymers were analyzed with .sup.1H-NMR and the monomer ratio in the copolymer calculated. The viscosities of the 5 wt % solutions of the copolymers in IPA were measured with a Viscolite VL7-100B-d15 of Hydramotion. The results are given in Table 1 below.
TABLE-US-00003 TABLE 1 Monomer ratio in copolymer Vibrational Viscosity Monomer ratio in Monomer ratio determined with (cP) 5 wt % solution in Copolymer feed (wt %): in feed (mol %): 1H-NMR (wt %): IPA at 20° C. ± 1° C. PVPM20-65:35 65:35 86.9:13.1 64.3:35.7 13 PVPM20-80:20 80:20 93.4:6.6 81.5:18.5 11* PVPM20-85:15 85:15 95.3:4.7 83.9:16.1 10 PVPM20-90:10 90:10 97.0:30 Not Not determined determined PVPMDV-60:40 60:40 77.6:22.4 60.8:39.2 16 PVPMDM-75:25 75:25 87.4:12.6 74.9:25.1 12 PVPMEM-70:30 70:30 89.3:10.7 70.1:29.9 11 PVPDDM-80:20 80:20 93.4:6.6 79.1:20.9 15 *PVPM20-80:20 (Mn 23.918 and Mw 35,654 determined with GPC using PEG standards) results in a viscosity of 11 cP in this mthod PVPM20
[0092] The different co-polymers (in short PVPM20, PVPMDM, PVPDDM and PVPMEM; see for the structures above) were dissolved to a final concentration of 2.5 wt % or 5 wt % in 2-propanol. The resulting copolymer solutions were then supplemented with different concentrations of BKC (Sigma Aldrich) or BEZ (Sigma Aldrich).
[0093] Co-Polymer Screening for Antimicrobial Activity
[0094] Antimicrobial activity screening was performed with an N-vinyl lactam copolymer obtainable by feeding a monomer mixture of VP and M20 at a 90% to 10% weight ratio, respectively, and supplemented with 0.1%, 0.5% or 1.0% BKC from a 50% (w/v) stock solution. PVPM20-90:10 without BKC, and BKC solutions of 0.1%, 0.5% or 1.0% without PVPM20 were used as controls. The different formulations were used to coat 96-well microtiter plates by applying different aliquots to the bottoms of the wells; 5 μl of the original 5% PVPM20 solutions, 2 μl and 5 μl of 0.5% PVPM20 solutions (10× diluted), and 2 μl and 5 μl of 0.05% PVPM20 solutions (100× diluted). The wells were air-dried, resulting in the deposition of a polymer film loaded with BKC on the bottom of the wells. The BKC controls were applied using the same approach. Next, 100 μl aliquots of a culture of exponentially growing S. aureus HG001 in TSB were added to the wells and growth was monitored for 14 hours by optical density readings at 600 nm (OD.sub.600) using a Biotek powerwave plate reader at maximal shaking.
[0095] Disk Diffusion Assay
[0096] PVPM20-90:10 (5%) formulations with either 0.1%, 0.5% or 1% BKC were spotted in 5 μl aliquots on 5 mm Whatman® paper disks. Also, 5 μl aliquots of 0.1%, 0.5% or 1% BKC solutions were spotted on the disks. After disk drying at room temperature, the disks were placed on TSA plates onto which S. aureus HG001 had been spread to obtain a confluent lawn of cells. These plates were then incubated overnight at 37° C. and, the next day, the sizes of the observed inhibition zones were measured to estimate the diffusion of BKC from the paper disks.
[0097] S. aureus Contamination and Transmission Assay
[0098] To assay the impact of different polymer formulations on the contamination of surfaces with S. aureus and the subsequent S. aureus transmission to other surfaces, a dedicated assay was developed. Briefly, an overnight culture of S. aureus HG001 was diluted 1:10.000 and 1 ml was plated confluently onto two large bioassay plates with TSA. After inoculation, the plates were dried at 37° C. for approximately 30 min to allow bacteria to settle and to remove access moisture. Nitrile examination gloves were wrapped around self-fabricated stamps (
[0099] BKC Release Assay
[0100] The different 5 wt % polymer formulations were supplemented with 0.45 wt % BKC and 20 μl coated to the first well of each row of a 96-well plate. After evaporation of the solvent (2-propanol), 100 μl of an aqueous BPB (BisPhenol Blue) solution (25×10.sup.−3 mmol/L) was added to the coated wells and the plate was incubated for 30 seconds at room temperature. Next, the aqueous phase was removed from the well and the formation of blue BPB-BKC complexes was assessed by visual inspection. This process was repeated until blue BPB-BKC complexes were no longer observed, and the number of repeated BPB incubation steps was recorded.
[0101] Glove Contamination Assay
[0102] Nitrile examination gloves (Sterling Nitrile Powder-Free Exam Gloves, Kimberly-Clark) were coated with 1 ml of PVPM20-80:20 (5 weight %) dissolved in 2-propanol and supplemented with 0.9% BKC. As a control, untreated nitrile examination gloves were used. Next, 13 volunteers were asked to wear a PVPM20-80:20 0.9% BKC-treated and an untreated examination glove (control), while performing their normal daily activities. To prevent a dominant hand bias, the coated glove was randomly assigned to the left or right hands of the volunteers. After ˜3 hours, both gloved hands were pressed gently on a LB agar plate which was then incubated overnight at 37° C. Images were recorded with a G:BOX gel documentation and analysis system (Syngene). The numbers of CFUs on the plate were automatically assigned using the Syngene software package. CFU numbers thus determined were used as a measure for the numbers of microbial contaminants that had adhered to the glove.
[0103] Hand Contamination Assay
[0104] Both hands of a volunteer were first decontaminated with Sterillium. Next, the volunteer was asked to apply 1 ml of a PVPM20-80:20 0.9 weight % BKC solution onto one hand by hand rubbing, and, therefore, the other hand was protected from coating with a nitrile examination glove. After approximately 3 hours of normal daily activities, both hands were pressed gently on a LB agar plate. Upon overnight incubation of the plate at 37° C., the microbial contamination of the hands of the volunteers was assessed by CFU counting as described for the glove contamination assay.
[0105] BKC, BEZ and PHMBH+Cl— Release Assay (for Comparison)
[0106] PVPDDM-80:20 2.5 wt % formulations were supplemented with 0.45 wt % BKC or BEZ or PHMBH+Cl—) and 20 μl coated to the first well of each row of a 96-well plate. After evaporation of the 2-propanol solvent, 100 μl water was added to the coated wells and the plate was incubated for 60 seconds at room temperature. Next, the aqueous phase was removed from the well. This process was repeated 7 times. Subsequently 5 μl aqueous phase of each well was brought on TSA-plates, which were inoculated confluently with S. aureus HG001. After overnight incubation at 37° C. the plates were visually inspected for growth inhibition zones.
Example 1: The PVP-M20 Copolymer can Function as Coating-Carrier for Antimicrobial Agents
[0107] This example describes the manufacture of a polymer film through a co-polymer formulation consisting of PVP and M20 (i.e. PVPM20). Co-polymers were prepared using a premixed monomer feed comprising different weight ratios of VP and M20. The different co-polymers (in short PVPM20) were dissolved to a final concentration of 5% in 2-propanol. The resulting PVPM20 solutions were then supplemented with different concentrations of BKC (Sigma Aldrich). The co-polymer antimicrobial activity screen was performed with a copolymer obtained using VP and M20, mixed at a 90% to 10% weight ratio (hereinafter: PVPM20-90:10), respectively, the copolymer being supplemented with 0.1%, 0.5% or 1.0% BKC from a 50% (w/v) stock solution.
[0108] PVPM20-90:10 without BKC, and BKC solutions of 0.1%, 0.5% or 1.0% without PVPM20 were used as controls. The different formulations were used to coat 96-well microtiter plates by applying different aliquots to the bottoms of the wells; 5 μl of the original 5% PVPM20 solutions, 2 μl and 5 μl of 0.5% PVPM20 solutions (10× diluted), and 2 μl and 5 μl of 0.05% PVPM20 solutions (100× diluted). The wells were air-dried, resulting in the deposition of a polymer film on the bottom of the wells. The BKC controls were applied using the same approach. Next, 100 μl aliquots of a culture of exponentially growing S. aureus HG001 (21) in TSB were added to the wells and growth was monitored for 14 hours by optical density readings at 600 nm (OD.sub.600) using a Biotek powerwave plate reader at maximal shaking.
[0109] Coatings with the PVPM20 polymer, but without BKC had no effect on growth of S. aureus HG001 at 37° C. as the cells that were introduced into the wells with only PVPM20-90:10 showed comparable growth rates as cells introduced into the untreated wells (
Example 2: The PVP-M20 Polymer System Acts as a Slow-Release Carrier for Antimicrobial Agents
[0110] The observation that the PVPM20-90:10 polymer formulation slightly decreased the antimicrobial effects of BKC suggested that the polymer coating of the microtiter plate inhibited the release of BKC into the culture medium. This idea was tested in a disk diffusion assay using Tryptic Soy Agar (TSA) plates confluently inoculated with S. aureus HG001. After overnight incubation at 37° C., the growth inhibition zones around the paper disks were examined. Upon comparison of the growth inhibition zones around paper disks with PVPM20-90:10 plus BKC or with BKC alone, but both containing BKC at the same concentration, it was clearly evident that PVPM20-90:10 indeed inhibited the diffusion of BKC into the surrounding agar medium. Already at a BKC concentration of 0.1 weight % the PVPM20-90:10 polymer resulted in a substantial reduction of the inhibition zone (
[0111] This inhibitory effect of PVPM20-90:10 on BKC diffusion became less prominent when higher concentrations of BKC were used. The latter observation can be explained by the higher concentration gradient of BKC in the PVPM20 relative to the surrounding agar medium, resulting in a faster release of the BKC and effectively more BKC that is available to diffuse from the paper disk into the surrounding agar medium. Alternatively, the PVPM20 coating may become saturated with BKC, allowing the BKC that is available in excess to diffuse rapidly from the paper disk into the surrounding agar medium. The fact that PVPM20-90:10 can set a limit to the diffusion of BKC into the surrounding medium implies that PVPM20 can represent an attractive slow-release carrier for antimicrobial compounds, such as BKC. In turn, this made the formulation an attractive candidate for further proof-of-principle studies on the antimicrobial microglove concept.
Example 3: The Antimicrobial PVP-M20 System Effectively Prevents S. aureus Transmission
[0112] In the initial experiments described above, VP and M20 were used as premix at a 90% to 10% weight ratio to prepare the copolymer. To evaluate the resulting VP:M20 ratio in the copolymer as a parameter for the properties of the co-polymer film that is to represent a microglove, three different copolymers were synthesized using premixed monomer feeds with different VP:M20 weight ratios, namely 90:10 (PVPM20-90:10), 85:15 (PVPM20-85:15), and 80:20 (PVPM20-80:20).
[0113] To assay the impact of different copolymer formulations on the contamination of surfaces with S. aureus and the subsequent S. aureus transmission to other surfaces, a dedicated assay was developed. Briefly, an overnight culture of S. aureus HG001 was diluted 1:10.000 and 1 ml was plated confluently onto two large bioassay plates with TSA. After inoculation, the plates were dried at 37° C. for approximately 30 min to allow bacteria to settle and to remove access moisture. Nitrile examination gloves were wrapped around self-fabricated stamps (
[0114] This in-house developed contamination and transmission assay convincingly demonstrated that, using the non-coated control stamps, transmission of S. aureus HG001 was detectable from the initially contaminated stamp to both the second and third stamps (
[0115] When stamps were coated with the original PVPM20-90:10 formulation containing 0.1% BKC (
[0116] Increasing the BKC concentration to 0.5%, 1%, 2% or 5% resulted in even larger clearing zones (
[0117] These findings indicate that, while the polymer film remained intact on the stamp, it was able to prevent stamp contamination with bacteria and their subsequent transmission. PVPM20-80:20 polymer films containing BKC concentrations of 1% or more released substantial amounts of BKC onto the inoculated bioassay plate, as reflected by large clearing zones (
Example 4: The PVP-M Coating Facilitates Slow Biocide Release
[0118] The slow release properties of the PVPM20, PVPMDM, PVPMEM and PVPDDM co-polymer formulations were verified in a BKC and a BEZ release test that were performed in 96-well plates. The different polymer formulations (i.e. PVPM20-85:15, PVPM20-80:20, PVPM20-65:35, PVPMDM-60:40, PVPMDM-75:25, PVPMEM-80:20 and PVPDDM-80:20 in 2-propanol at 2.5 wt % were supplemented with 0.45 wt % BKC or BEZ. 20 μl was coated to the first well of each row of a 96-well plate. After evaporation of the 2-propanol solvent, 100 μl of an aqueous BPB solution (25×10.sup.−3 mmol/L) was added to the coated wells and the plate was incubated for 30 seconds at room temperature. BPB forms a blue complex with free BKC and free BEZ when it is released from the polymer film into an aqueous solution. Of note, the BPB-BKC or BPB-BEZ complex is blue, whereas the BPB solution itself is purple (20). Next, the aqueous phase was removed from the well and the formation of blue BPB-BKC or BPB-BEZ complexes was assessed by visual inspection. This process was repeated until blue BPB-BKC complexes were no longer observed, and the number of repeated BPB incubation steps was recorded.
[0119] The number of cycles needed to release readily detectable amounts of BKC or BEZ was used as a measure to assess the BKC-retaining or BEZ—retaining properties of the different polymer formulations.
[0120] The polymer film in the first well made with the PVPM20-65:35 formulation and that of the PVPMEM-70:30 formulation broke in small pieces after contact with water. These copolymers apparently are too hydrophobic for homogenously encapsulating BKC and BEZ, the particular biocides subject of this example. The enlarged BKC and/or BEZ domains so formed rapidly disrupt the films upon dissolving in contact with water. The test was stopped after one incubation cycle for these formulations. The PVPMDM-60:40 formulation did not release BKC or BEZ in 30 seconds in contact with BPB solution, because of a too slow release.
[0121] The PVPM20-80:20 formulation, the PVPM20-85:15 formulation and the PVPMDM-75:25 formulation were very efficient in releasing BKC or BEZ from the film as it took up to 7-8 consecutive incubations with the aqueous BPB solution until BKC or BEZ was no longer detectably released. The test showed that the PVPDDM-80:20 formulation was far most efficient in releasing BKC as well as BEZ from the film as it took up to 11 consecutive incubations with the aqueous BPB solution until BKC or BEZ was no longer detectably released. Additionally and as reference, we tested the BKC and the BEZ release from a 0.45% BKC and 0.45% BEZ coating without PVPM20-80:20. In this case, all coated material dissolved instantaneously upon addition of the BPB solution and all BKC was thereby released. Of note, the BKC or BEZ concentration in commercially available formulations is lower (˜0.2%) than the concentration used in our present polymer formulations. However, the BKC-release assay and BEZ-release assay shows that by using BKC or BEZ in combination with the copolymers PVPM20-80:20, PVPMDM-75:25 and PVPDDM-80:20, the actual release of free BKC or BEZ from the polymer film is considerably lower than that of unaided BKC or BEZ as implemented in commercial BKC- and BEZ-based disinfectants.
[0122] Combined with the other data presented above, it can thus be concluded that the high concentration of microbial agent is retained within the PVPM20-80:20, PVPMDM-75:25 and PVPDDM-80:20 copolymer film and that is only slowly released upon contact with water. This slow release combined with the good film properties demonstrates that the formulation meets the basic requirements for a hand rub that facilitates the establishment of an antimicrobial microglove.
[0123] A PVPMEM-80:20 formulation was not prepared, however studying the results and observing the trends it is conceivable that PVPMEM-80:20 will also give good slow release properties upon contact with water
[0124] An overview of the results are given in Table 2 below.
TABLE-US-00004 TABLE 2 Monomer ratio Film Test1 Test2 Copolymer in feed (wt %): breaks (BKC) (BEZ) PVPM20-65:35 65:35 yes Film ND breaks PVPM20-80:20 80:20 no 7x 7x PVPM20-85:15 85:15 no 7x ND PVPMDM-60:40 60:40 yes No ND release PVPMDM-75:25 75:25 no 8x ND PVPMEM-70:30 70:30 yes Film ND breaks PVPDDM-80:20 80:20 no 11x 11x BKC only NA NA 1x NA BEZ only NA NA NA 1x Test1: Biocide BKC: Number of incubations after which BKC was no longer detectable Test 2: Biocide BEZ: Number of incubations after which BEZ was no longer detectable ND = not determined, NA = not applicable
Example 5: Copolymer PVP-DDM-80:20 Facilitates Slow Release of Different Types of Biocides
[0125] Exemplary N-vinyl lactam copolymer of the invention PVPDDM-80:20 at 2.5 wt % in 2-propanol was supplemented with 0.45 wt % of the bactericidal agent BKC, BEZ or PHMBH+Cl—. Twenty μ1 was coated to the first well of each row of a 96-well plate. After evaporation of the solvent, 100 μl of water was added to the coated wells and the plate was incubated for 1 minute at room temperature. Next, the aqueous phase was removed from the well. This process was repeated 7 times. Depending on the degree of interaction with the polymer matrix, biocide will be slowly released to a certain extent into water during incubation. Five μ1 of each incubation step was brought on TSA-plates which were inoculated confluently with S. aureus HG001. After overnight incubation at 37° C. the plates were visually inspected for growth inhibition zones. The number of cycles after which growth inhibition was observed were 4, 4 and 3 for the formulations supplemented with BKC, BEZ, or PHMBH+Cl—) respectively (see also
Example 6: Validation of the Antimicrobial Microglove Concept
[0126] This example shows that the PVPM20-80:20 0.9% BKC formulation can function as a microglove that offers protection against microbial contamination, as was demonstrated using a glove contamination assay. [0127] Nitrile examination gloves (Sterling Nitrile Powder-Free Exam Gloves, Kimberly-Clark) were coated with 1 ml of an antimicrobial composition comprising PVPM20-80:20 (5 weight %) dissolved in 2-propanol and supplemented with 0.9% BKC. As a control, untreated nitrile examination gloves were used. Next, 13 volunteers were asked to wear on one hand a treated (coated) glove and on the other hand an untreated examination glove (control), while performing their normal daily activities. To prevent a dominant hand bias, the coated glove was randomly assigned to the left or right hands of the volunteers. After ˜3 hours, both gloved hands were pressed gently on a LB agar plate which was then incubated overnight at 37° C. Images were recorded with a G:BOX gel documentation and analysis system (Syngene). The numbers of CFUs on the plate were automatically assigned using the Syngene software package. CFU numbers thus determined were used as a measure for the numbers of microbial contaminants that had adhered to the glove.
[0128] As shown in
[0129] Since the surface of a nitrile examination glove only mimics the situation on the human skin, we decided to test the microglove concept on the hands of three volunteers, which was acceptable since the components of the antimicrobial composition can be considered as safe based on the well-known biocompatibility of PVP polymers.
[0130] Both hands of a volunteer were first decontaminated with an alcohol based handrub (Sterillium®). Next, the volunteer was asked to apply 1 ml of a PVPM20-80:20 0.9% BKC solution onto one hand by hand rubbing, and, therefore, the other hand was protected from coating with a nitrile examination glove. To prevent a dominant hand bias, the coated glove was randomly assigned to the left or right hands of the volunteers. Thus, for each volunteer one hand was treated with the polymer formulation, while the other hand remained untreated. After approximately 3 hours of normal daily activities, both hands were pressed gently on a LB agar plate. Upon overnight incubation of the plate at 37° C., the microbial contamination of the hands of the volunteers was assessed by CFU counting as described for the glove contamination assay. This analysis revealed that hands coated with the polymer-based formulation showed a significant reduction in CFU counts (
REFERENCES
[0131] 1. de Kraker, M. E., Davey, P. G., Grundmann, H.; BURDEN study group. (2011) Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: Estimating the burden of antibiotic resistance in europe. PLoS Med., 8, e1001104 [0132] 2. Parvizi, J., Pawasarat, I. M., Azzam, K. A., Joshi, A., Hansen, E. N. and Bozic, K. J. (2010) Periprosthetic joint infection: The economic impact of methicillin-resistant infections. J. Arthroplasty, 25, 103-107. [0133] 3. de Kraker, M. E., Wolkewitz, M., Davey, P. G., Koller, W., Berger, J., Nagler, J., Icket, C., Kalenic, S. et al. (2011) Clinical impact of antimicrobial resistance in european hospitals: Excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob. Agents Chemother., 55, 1598-1605. [0134] 4. de Kraker, M. E., Wolkewitz, M., Davey, P. G., Koller, W., Berger, J., Nagler, J., Icket, C., Kalenic, S. et al. (2011) Burden of antimicrobial resistance in european hospitals: Excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J. Antimicrob. Chemother., 66, 398-407. [0135] 5. Ciccolini, M., Donker, T., Grundmann, H., Bonten, M. J. and Woolhouse, M. (2014) Efficient surveillance for healthcare-associated infections spreading between hospitals. Proc. Natl. Acad. Sci. U.S.A, 111, 2271-2276. [0136] 6. Donker, T., Wallinga, J. and Grundmann, H. (2014) Dispersal of antibiotic-resistant high-risk clones by hospital networks: Changing the patient direction can make all the difference. J. Hosp. Infect., 86, 34-41. [0137] 7. Pittet, D., Allegranzi, B., Sax, H., Dharan, S., Pessoa-Silva, C. L., Donaldson, L. and Boyce, J. M. (2006) Evidence-based model for hand transmission during patient care and the role of improved practices. Lancet Infect. Dis., 6, 641-652. [0138] 8. Ciccolini, M., Donker, T., Kock, R., Mielke, M., Hendrix, R., Jurke, A., Rahamat-Langendoen, J., Becker, K., et al. (2013) Infection prevention in a connected world: The case for a regional approach. Int. J. Med. Microbiol., 303, 380-387. [0139] 9. Kretzer, E. K. and Larson, E. L (1998) Behavioral interventions to improve infection control practices. Am. J. Infect. Control, 26, 245-253. [0140] 10. Curtis, V. and Carincross, S. (2003) Effect of washing hands with soap on diarrhoea risk in the community: A systematic review. Lancet Infect Dis, 3, 275-281. [0141] 11. WHO. (2000) World health report 2000. [0142] 12. Pittet, D. (2001) Compliance with hand disinfection and its impact on hospital-acquired infections. J. Hosp. Infect., 48, 40-46. [0143] 13. Allegranzi, B. and Pittet, D. (2009) Role of hand hygiene in healthcare-associated infection prevention. J. Hosp. Infect., 73, 305-315. [0144] 14. Randle, J., Arthur, A. and Vaughan, N. (2010) Twenty-four-hour observational study of hospital hand hygiene compliance. J. Hosp. Infect., 76, 252-255. [0145] 15. Larson, E. and Killien, M. (1982) Factors influencing handwashing behavior of patient care personnel. Am. J. Infect. Control, 10, 93-99. [0146] 16. Steere, A. C. and Mallison, G. F. (1975) Handwashing practices for the prevention of nosocomial infections. Ann. Intern. Med., 83, 683-690. [0147] 17. Ulmer, H. W. and Flipsen, T. A. (2014) Maleate-based copolymers and methods for preparing the same. WO2011/002278 [0148] 18. Patarca, R., Rosenzwei, J. A., Zuniga, A. A., and Fletcher, M. A. (2000) Benzalkonium salts: Effects on G protein-mediated processes and surface membranes. Crit. Rev. Oncog., 11, 255-305. [0149] 19. Basketter, D. A., Marriott, M., Gilmour, N. J. and White, I. R. (2004-4) Strong irritants masquerading as skin allergens: The case of benzalkonium chloride. Contact Derm., 50, 213-217. [0150] 20. Yamamoto, K. (1995) Sensitive determination of quaternary ammonium salts by extraction-spectrophotometry of ion associates with bromophenol blue anion and coextraction. Anal. Chim. Acta., 302, 75-79. [0151] 21. Herbert, S., Ziebandt, A. K., Ohlsen, K., Schäfer, T., Hecker, M., Albrecht, D., Novick, R. and Gotz, F. (2010) Repair of global regulators in Staphylococcus aureus 8325 and comparative analysis with other clinical isolates. Infect. Immun., 78, 2877-2889.